Is Celestica The Best AI Stock to Buy Now?
Technology and hardware business Celestica (NYSE:CLS) has seen massive upward…
Sell
29
ZLAB Quote, Financials, Valuation and Earnings
Last price:
$20.06
Seasonality move
:
-4.51%
Day range:
$19.60 - $20.21
52-week range:
$15.96 - $44.34
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
4.87x
P/B ratio:
2.96x
Volume:
521K
Avg. volume:
733.6K
1-year change:
-35.33%
Market cap:
$2.2B
Revenue:
$399.2M
EPS (TTM):
-$1.95
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
ZLAB
Zai Lab Ltd.
|
$122.7M | -$0.42 | 17.43% | -30.7% | $43.42 |
|
CASI
CASI Pharmaceuticals, Inc.
|
-- | -- | -100% | -- | $4.00 |
|
CCM
Concord Medical Services Holdings Ltd.
|
-- | -- | -- | -- | -- |
|
RDY
Dr. Reddy's Laboratories Ltd.
|
$929.2M | $0.19 | -4.64% | 3.83% | $14.32 |
|
SVA
Sinovac Biotech Ltd.
|
-- | -- | -- | -- | -- |
|
YI
111, Inc.
|
$514.9M | -- | -4.26% | -- | -- |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
ZLAB
Zai Lab Ltd.
|
$20.04 | $43.42 | $2.2B | -- | $0.00 | 0% | 4.87x |
|
CASI
CASI Pharmaceuticals, Inc.
|
$0.77 | $4.00 | $15.7M | -- | $0.00 | 0% | 0.45x |
|
CCM
Concord Medical Services Holdings Ltd.
|
$3.48 | -- | $15.1M | -- | $0.00 | 0% | 0.30x |
|
RDY
Dr. Reddy's Laboratories Ltd.
|
$14.49 | $14.32 | $12.1B | 18.59x | $0.09 | 0.64% | 3.05x |
|
SVA
Sinovac Biotech Ltd.
|
$6.47 | -- | $464.9M | -- | $55.00 | 0% | 1.50x |
|
YI
111, Inc.
|
$8.18 | -- | $70.9M | -- | $0.00 | 0% | 0.04x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
ZLAB
Zai Lab Ltd.
|
22.4% | -0.192 | 5.85% | 2.56x |
|
CASI
CASI Pharmaceuticals, Inc.
|
-274.41% | -0.389 | 55.28% | 0.19x |
|
CCM
Concord Medical Services Holdings Ltd.
|
273.84% | -1.505 | 77.28% | 0.19x |
|
RDY
Dr. Reddy's Laboratories Ltd.
|
15.39% | 0.028 | 6.43% | 1.19x |
|
SVA
Sinovac Biotech Ltd.
|
3.46% | 7.263 | 12.91% | 11.22x |
|
YI
111, Inc.
|
-42.73% | -1.247 | 17.3% | 0.41x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
ZLAB
Zai Lab Ltd.
|
$69.3M | -$48.9M | -21.74% | -26.7% | -42.05% | -$44.5M |
|
CASI
CASI Pharmaceuticals, Inc.
|
$706K | -$10.2M | -405.32% | -70405.41% | -333.14% | -- |
|
CCM
Concord Medical Services Holdings Ltd.
|
-- | -- | -7.49% | -19.78% | -- | -- |
|
RDY
Dr. Reddy's Laboratories Ltd.
|
$525.4M | $154.2M | 13.68% | 15.8% | 15.74% | $32.9M |
|
SVA
Sinovac Biotech Ltd.
|
-- | -- | -1.02% | -1.05% | -- | -- |
|
YI
111, Inc.
|
$24.9M | -$302.8K | -15.3% | -26.11% | -0.07% | $5.3M |
Zai Lab Ltd. vs. Competitors
-
Which has Higher Returns ZLAB or CASI?
CASI Pharmaceuticals, Inc. has a net margin of -30.98% compared to Zai Lab Ltd.'s net margin of -353.92%. Zai Lab Ltd.'s return on equity of -26.7% beat CASI Pharmaceuticals, Inc.'s return on equity of -70405.41%.
Company Gross Margin Earnings Per Share Invested Capital ZLABZai Lab Ltd.59.62% -$0.33 $979.3M CASICASI Pharmaceuticals, Inc.22.96% -$0.68 -$6.9M -
What do Analysts Say About ZLAB or CASI?
Zai Lab Ltd. has a consensus price target of $43.42, signalling upside risk potential of 116.67%. On the other hand CASI Pharmaceuticals, Inc. has an analysts' consensus of $4.00 which suggests that it could grow by 422.81%. Given that CASI Pharmaceuticals, Inc. has higher upside potential than Zai Lab Ltd., analysts believe CASI Pharmaceuticals, Inc. is more attractive than Zai Lab Ltd..
Company Buy Ratings Hold Ratings Sell Ratings ZLABZai Lab Ltd.8 1 0 CASICASI Pharmaceuticals, Inc.1 0 0 -
Is ZLAB or CASI More Risky?
Zai Lab Ltd. has a beta of 0.879, which suggesting that the stock is 12.141% less volatile than S&P 500. In comparison CASI Pharmaceuticals, Inc. has a beta of 0.866, suggesting its less volatile than the S&P 500 by 13.412%.
-
Which is a Better Dividend Stock ZLAB or CASI?
Zai Lab Ltd. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. CASI Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Zai Lab Ltd. pays -- of its earnings as a dividend. CASI Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios ZLAB or CASI?
Zai Lab Ltd. quarterly revenues are $116.2M, which are larger than CASI Pharmaceuticals, Inc. quarterly revenues of $3.1M. Zai Lab Ltd.'s net income of -$36M is lower than CASI Pharmaceuticals, Inc.'s net income of -$10.9M. Notably, Zai Lab Ltd.'s price-to-earnings ratio is -- while CASI Pharmaceuticals, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Zai Lab Ltd. is 4.87x versus 0.45x for CASI Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income ZLABZai Lab Ltd.4.87x -- $116.2M -$36M CASICASI Pharmaceuticals, Inc.0.45x -- $3.1M -$10.9M
-
Which has Higher Returns ZLAB or CCM?
Concord Medical Services Holdings Ltd. has a net margin of -30.98% compared to Zai Lab Ltd.'s net margin of --. Zai Lab Ltd.'s return on equity of -26.7% beat Concord Medical Services Holdings Ltd.'s return on equity of -19.78%.
Company Gross Margin Earnings Per Share Invested Capital ZLABZai Lab Ltd.59.62% -$0.33 $979.3M CCMConcord Medical Services Holdings Ltd.-- -- $727.8M -
What do Analysts Say About ZLAB or CCM?
Zai Lab Ltd. has a consensus price target of $43.42, signalling upside risk potential of 116.67%. On the other hand Concord Medical Services Holdings Ltd. has an analysts' consensus of -- which suggests that it could grow by 244.83%. Given that Concord Medical Services Holdings Ltd. has higher upside potential than Zai Lab Ltd., analysts believe Concord Medical Services Holdings Ltd. is more attractive than Zai Lab Ltd..
Company Buy Ratings Hold Ratings Sell Ratings ZLABZai Lab Ltd.8 1 0 CCMConcord Medical Services Holdings Ltd.0 0 0 -
Is ZLAB or CCM More Risky?
Zai Lab Ltd. has a beta of 0.879, which suggesting that the stock is 12.141% less volatile than S&P 500. In comparison Concord Medical Services Holdings Ltd. has a beta of -1.213, suggesting its less volatile than the S&P 500 by 221.26%.
-
Which is a Better Dividend Stock ZLAB or CCM?
Zai Lab Ltd. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Concord Medical Services Holdings Ltd. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Zai Lab Ltd. pays -- of its earnings as a dividend. Concord Medical Services Holdings Ltd. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios ZLAB or CCM?
Zai Lab Ltd. quarterly revenues are $116.2M, which are larger than Concord Medical Services Holdings Ltd. quarterly revenues of --. Zai Lab Ltd.'s net income of -$36M is higher than Concord Medical Services Holdings Ltd.'s net income of --. Notably, Zai Lab Ltd.'s price-to-earnings ratio is -- while Concord Medical Services Holdings Ltd.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Zai Lab Ltd. is 4.87x versus 0.30x for Concord Medical Services Holdings Ltd.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income ZLABZai Lab Ltd.4.87x -- $116.2M -$36M CCMConcord Medical Services Holdings Ltd.0.30x -- -- --
-
Which has Higher Returns ZLAB or RDY?
Dr. Reddy's Laboratories Ltd. has a net margin of -30.98% compared to Zai Lab Ltd.'s net margin of 13.63%. Zai Lab Ltd.'s return on equity of -26.7% beat Dr. Reddy's Laboratories Ltd.'s return on equity of 15.8%.
Company Gross Margin Earnings Per Share Invested Capital ZLABZai Lab Ltd.59.62% -$0.33 $979.3M RDYDr. Reddy's Laboratories Ltd.53.64% $0.16 $4.9B -
What do Analysts Say About ZLAB or RDY?
Zai Lab Ltd. has a consensus price target of $43.42, signalling upside risk potential of 116.67%. On the other hand Dr. Reddy's Laboratories Ltd. has an analysts' consensus of $14.32 which suggests that it could fall by -1.15%. Given that Zai Lab Ltd. has higher upside potential than Dr. Reddy's Laboratories Ltd., analysts believe Zai Lab Ltd. is more attractive than Dr. Reddy's Laboratories Ltd..
Company Buy Ratings Hold Ratings Sell Ratings ZLABZai Lab Ltd.8 1 0 RDYDr. Reddy's Laboratories Ltd.2 2 1 -
Is ZLAB or RDY More Risky?
Zai Lab Ltd. has a beta of 0.879, which suggesting that the stock is 12.141% less volatile than S&P 500. In comparison Dr. Reddy's Laboratories Ltd. has a beta of 0.346, suggesting its less volatile than the S&P 500 by 65.442%.
-
Which is a Better Dividend Stock ZLAB or RDY?
Zai Lab Ltd. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Dr. Reddy's Laboratories Ltd. offers a yield of 0.64% to investors and pays a quarterly dividend of $0.09 per share. Zai Lab Ltd. pays -- of its earnings as a dividend. Dr. Reddy's Laboratories Ltd. pays out 8.91% of its earnings as a dividend. Dr. Reddy's Laboratories Ltd.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios ZLAB or RDY?
Zai Lab Ltd. quarterly revenues are $116.2M, which are smaller than Dr. Reddy's Laboratories Ltd. quarterly revenues of $979.5M. Zai Lab Ltd.'s net income of -$36M is lower than Dr. Reddy's Laboratories Ltd.'s net income of $133.5M. Notably, Zai Lab Ltd.'s price-to-earnings ratio is -- while Dr. Reddy's Laboratories Ltd.'s PE ratio is 18.59x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Zai Lab Ltd. is 4.87x versus 3.05x for Dr. Reddy's Laboratories Ltd.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income ZLABZai Lab Ltd.4.87x -- $116.2M -$36M RDYDr. Reddy's Laboratories Ltd.3.05x 18.59x $979.5M $133.5M
-
Which has Higher Returns ZLAB or SVA?
Sinovac Biotech Ltd. has a net margin of -30.98% compared to Zai Lab Ltd.'s net margin of --. Zai Lab Ltd.'s return on equity of -26.7% beat Sinovac Biotech Ltd.'s return on equity of -1.05%.
Company Gross Margin Earnings Per Share Invested Capital ZLABZai Lab Ltd.59.62% -$0.33 $979.3M SVASinovac Biotech Ltd.-- -- $11.8B -
What do Analysts Say About ZLAB or SVA?
Zai Lab Ltd. has a consensus price target of $43.42, signalling upside risk potential of 116.67%. On the other hand Sinovac Biotech Ltd. has an analysts' consensus of -- which suggests that it could fall by --. Given that Zai Lab Ltd. has higher upside potential than Sinovac Biotech Ltd., analysts believe Zai Lab Ltd. is more attractive than Sinovac Biotech Ltd..
Company Buy Ratings Hold Ratings Sell Ratings ZLABZai Lab Ltd.8 1 0 SVASinovac Biotech Ltd.0 0 0 -
Is ZLAB or SVA More Risky?
Zai Lab Ltd. has a beta of 0.879, which suggesting that the stock is 12.141% less volatile than S&P 500. In comparison Sinovac Biotech Ltd. has a beta of 0.746, suggesting its less volatile than the S&P 500 by 25.394%.
-
Which is a Better Dividend Stock ZLAB or SVA?
Zai Lab Ltd. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Sinovac Biotech Ltd. offers a yield of 0% to investors and pays a quarterly dividend of $55.00 per share. Zai Lab Ltd. pays -- of its earnings as a dividend. Sinovac Biotech Ltd. pays out -328.35% of its earnings as a dividend.
-
Which has Better Financial Ratios ZLAB or SVA?
Zai Lab Ltd. quarterly revenues are $116.2M, which are larger than Sinovac Biotech Ltd. quarterly revenues of --. Zai Lab Ltd.'s net income of -$36M is higher than Sinovac Biotech Ltd.'s net income of --. Notably, Zai Lab Ltd.'s price-to-earnings ratio is -- while Sinovac Biotech Ltd.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Zai Lab Ltd. is 4.87x versus 1.50x for Sinovac Biotech Ltd.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income ZLABZai Lab Ltd.4.87x -- $116.2M -$36M SVASinovac Biotech Ltd.1.50x -- -- --
-
Which has Higher Returns ZLAB or YI?
111, Inc. has a net margin of -30.98% compared to Zai Lab Ltd.'s net margin of -0.5%. Zai Lab Ltd.'s return on equity of -26.7% beat 111, Inc.'s return on equity of -26.11%.
Company Gross Margin Earnings Per Share Invested Capital ZLABZai Lab Ltd.59.62% -$0.33 $979.3M YI111, Inc.5.93% -$0.21 $59.5M -
What do Analysts Say About ZLAB or YI?
Zai Lab Ltd. has a consensus price target of $43.42, signalling upside risk potential of 116.67%. On the other hand 111, Inc. has an analysts' consensus of -- which suggests that it could grow by 634%. Given that 111, Inc. has higher upside potential than Zai Lab Ltd., analysts believe 111, Inc. is more attractive than Zai Lab Ltd..
Company Buy Ratings Hold Ratings Sell Ratings ZLABZai Lab Ltd.8 1 0 YI111, Inc.0 0 0 -
Is ZLAB or YI More Risky?
Zai Lab Ltd. has a beta of 0.879, which suggesting that the stock is 12.141% less volatile than S&P 500. In comparison 111, Inc. has a beta of 0.674, suggesting its less volatile than the S&P 500 by 32.648%.
-
Which is a Better Dividend Stock ZLAB or YI?
Zai Lab Ltd. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. 111, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Zai Lab Ltd. pays -- of its earnings as a dividend. 111, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios ZLAB or YI?
Zai Lab Ltd. quarterly revenues are $116.2M, which are smaller than 111, Inc. quarterly revenues of $419.3M. Zai Lab Ltd.'s net income of -$36M is lower than 111, Inc.'s net income of -$2.1M. Notably, Zai Lab Ltd.'s price-to-earnings ratio is -- while 111, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Zai Lab Ltd. is 4.87x versus 0.04x for 111, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income ZLABZai Lab Ltd.4.87x -- $116.2M -$36M YI111, Inc.0.04x -- $419.3M -$2.1M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Will AI Disrupt SaaS Software Stocks?
Since January 28th, software stocks in the United States have…
Why Is Meta Stock Going Higher?
Over the last five days, shares of Instagram and Facebook…
Stock Ideas
Buy
55
Is NVDA Stock a Buy?
Market Cap: $4.6T
P/E Ratio: 65x
Sell
50
Is AAPL Stock a Buy?
Market Cap: $3.9T
P/E Ratio: 35x
Sell
40
Is GOOGL Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 29x
Alerts
Buy
77
RNG alert for Feb 21
RingCentral, Inc. [RNG] is up 34.37% over the past day.
Sell
9
FROG alert for Feb 21
JFrog Ltd. [FROG] is down 24.98% over the past day.
Buy
72
SNSE alert for Feb 21
Sensei Biotherapeutics, Inc. [SNSE] is up 23.81% over the past day.
